What do systematic reviews say?

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  HR 0.92 [0.8, 1.05]
  10 studies · 3843 participants
  Low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  HR 0.9 [0.78, 1.04]
  11 studies · 4014 participants
  Low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 53 participants
  Very low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall response rate Duration of compared with chemotherapy alone (low certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  OR 1.24 [1, 1.55]
  11 studies · 3723 participants
  Low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher adverse event (any) Duration of compared with chemotherapy alone (moderate certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  OR 2.23 [1.27, 3.92]
  5 studies · 2290 participants
  Moderate

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher severe adverse event (grade ≥ 3 ) Duration of compared with chemotherapy alone (moderate certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  OR 1.19 [1.03, 1.37]
  8 studies · 3800 participants
  Moderate